Summary
This Mendelian randomisation study characterised the metabolomic signatures of 8 lipid-modifying drug targets using genetic data from over 115,000 UK Biobank participants. The findings reveal that drug targets within the same therapeutic class (e.g. HMGCR and PCSK9 for LDL lowering) produce highly correlated metabolomic effects (r² = 0.91), whilst targets across different drug classes designed to modify distinct lipoprotein traits have markedly disparate metabolomic signatures (r² < 0.02). Notably, triglyceride-modifying therapies showed stronger effects on inflammatory markers than LDL-lowering therapies, suggesting potential implications for therapeutic selection and biomarker development beyond coronary artery disease risk reduction.
UK applicability
These findings apply directly to United Kingdom clinical practice and drug development, as the study population comprises UK Biobank participants. The results may inform stratification of lipid-modifying therapies in the NHS and support more personalised approaches to cardiovascular risk reduction by considering metabolomic signatures alongside traditional lipid endpoints.
Key measures
Genetic risk scores for 8 drug targets (HMGCR, PCSK9, NPC1L1, CETP, APOC3, ANGPTL3, ANGPTL4, LPL); effects on 249 metabolic traits; coronary artery disease risk; consistency of effects between drug targets (r² comparisons); effects on glycoprotein acetyls and inflammatory biomarkers
Outcomes reported
The study estimated the genetically predicted effects of 8 lipid-modifying drug targets on 249 metabolic traits in up to 115,082 UK Biobank participants. It characterised the breadth and specificity of metabolomic signatures across drug classes designed to modify different lipoprotein lipid traits.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.